Voriconazole: A new triazole antifungal agent

Annals of Pharmacotherapy

Volumn 37, Issue 3, 2003, Pages 420-432

  Pearson, Margaret M ^a   Rogers, P David ^b   Cleary, John D ^c   Chapman, Stanley W ^c   Da Camara, Carlos ^d   Perreault, Marc M ^d  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

Antifungal; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ASTEMIZOLE; CISAPRIDE; CYCLOSPORIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ERGOT ALKALOID; FELODIPINE; FLUCONAZOLE; FLUCYTOSINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIDAZOLAM; OMEPRAZOLE; PHENYTOIN; PIMOZIDE; QUINIDINE; RAPAMYCIN; TACROLIMUS; TERBINAFINE; TERFENADINE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CHOLESTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHYTE; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; ERYTHEMA; FEVER; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HEPATITIS; HUMAN; HYPOGLYCEMIA; IMMUNE DEFICIENCY; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION TEST; LIVER METABOLISM; LUPUS VULGARIS; MEDLINE; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NEUTROPENIA; PHOTOSENSITIVITY DISORDER; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; RASH; TERATOGENICITY; VISUAL DISORDER;

EID: 0037371098     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C261     Document Type: Article

References (83)

1. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001;33:1692-6.
2. Richardson K, Bell AS, Dickinson RP, Narayanaswami S, Ray SJ. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Synthesis and SAR (abstract F69). In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 18, 1995:125.
3. Troke PF, Bell AS, Dickinson RP, Hitchcock CA, Jezequel S, Narayanaswami S, et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of systemic fungal infections: Discovery and antifungal properties (abstract F70). In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 18, 1995:125.
4. Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997;41:2492-6.
5. Johnston D, Zhou X, Fukuoka T, Winslow CA, De Groot MJ, Burt C, et al. Voriconazole is highly active against the 14α-demethylase of Candida krusei (abstact 2073). In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 29, 1999:586.
6. Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum, M. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997;41:1840-2.
7. Abraham OC, Manavathu EK, Cutright JL, Chandrasekar PH. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Mycology 1999;33:7-11.
8. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998;42:741-5.
9. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999:37:3946-51.
10. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998;36:198-202.
11. Oakley KL, Moore CB, Denning DW. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother 1998;42:91-4.
12. Verweij PE, Mensink M, Rijs AJMM, Donnelly JP, Meis JFGM, Denning DW. In-vitro activities of amphotericin B, itraconazole, and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother 1998;42:389-92.
13. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole, and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998;42:531-3.
14. Wildfeuer A, Seidl HP, Paule I, Haberreiter A. In vitro activity of voriconaozle against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and grisefulvin. Arzeimittelforschung 1997;47:1257-63.
15. Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voficonazole against Aspergillus and Fusarium species. Eur J Clin Microbial Infect Dis 1998;17:573-5.
16. Kauffman CA, Zarins LT. In vitro activity of voriconazole against Candida species. Diag Microbial Infect Dis 1998;31:297-300.
17. Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, et al. International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diag Microbiol Infect Dis 1999;35:19-25.
18. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 1998;42:3242-4.
19. Marco F, Pfaller MA, Messer S, Jones RN. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother 1998;42:161-3.
20. Barry AL, Brown SD. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother 1996;40:1948-9.
21. Hoban DJ, Zhanel GG, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob Agents Chemother 1999;43:1463-4.
22. Chavez M, Bernal S, Valverde A, Gutierrez MJ, Quindos G, Martin Mazuelos E. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Clin Microbiol 1999;44:697-700.
23. Nguyen MH, Yu CY. Voriconazole against fluconazole-susceptible and -resistant Candida isolates: in-vitro efficacy compared with that of itraconazole and ketaconazole. J Antimicrob Chemother 1998;42:253-6.
24. Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000;44:1734-6.
25. Nguyen MH, Yu CY. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother 1998;42:471-2.
26. Pfaller MA, Zhang J, Messer SA, Brandt ME, Hajjeh RA, Jessup CJ, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 1999;43:169-71.
27. Package insert. VFEND Tablets/VFEND I.V. (voriconazole). New York: Pfizer Roerig, May 2002.
28. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998;42:3018-21.
29. Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 2001;39:91-5.
30. Vora S, Chauhan S, Brummer E, Stevens DA. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocytemacrophage colony-stimulating factor. Antimicrob Agents Chemother 1998;42:2299-303.
31. Johnston D, Cannom RRM, Filler SG. Amino acid substitutions in the Aspergillus fumigatus ERG11 gene product render it resistant to itraconazole yet susceptibility to voriconazole is maintained (abstract 1953). In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 19, 2000:394.
32. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001;39:954-8.
33. Klepser ME, Malone D, Lewis RE, Ernst EJ, Pfaller MA. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 2000;44:1917-20.
34. Vora S, Purimetla N, Brummer E, Stevens DA. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocytemacrophage colony-stimulating factor. Antimicrob Agents Chemother 1998;42:907-10.
35. Fratti RA, Belanger PH, Sanati H, Ghannoum MA. The effect of the new triazole, voriconazole (UK-109,496), on the interactions of Candida albicans and Candida krusei with endothelial cells. J Chemother 1998;10:7-16.
36. Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother 2000;34:1032-43.
37. Garcia MT, Llorente MT, Lima JE, Minguez F, Del Moral F, Prieto J. Activity of voriconazole: post-antifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. Scand J Infect Dis 1999:31:501-4.
38. Weig M, Muller FC. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2001;45:966-8.
39. Rieg G, Johnston D, Ibrahim A, Filler S, Edwards JE Jr. In vitro activity of voriconazole in combination with amphotericin B of 5 flucytosine against clinical fluconazole-resistant Candida albicans (abstract J-11). In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 25, 1998:453.
40. Sanglard D, Ischer F, Bille J. Interactions of voriconazole (VCZ) with yeast multidrug efflux transporters and different cytochrome P450 mutant forms (abstract 1711). In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 19, 2000:393.
41. Ostrosky-Zeichner L, Paetznick VL, Rodriquez JR, Chen E, Rex JH. In vitro antifungal susceptibilities of Trichosporon species (abstract 935). In: Program and abstracts of the 40 th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 18, 2000:369.
42. Gupta AK, Kohli Y, Li A, Faergemann J, Summerbell RC. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. Br J Dermatol 2000;142:758-65.
43. Marco F, Pfaller MA, Messer SA, Jones RN. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol 1998;36:433-6.
44. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR Jr, Pinaldi MG. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 1997:41:1832-4.
45. McGinnis MR, Pasarell L, Cooper CR Jr. In vitro susceptibility of clinical mould isolates to UK-109,496, amphotericin B, fluconazole, and itraconazole (abstract E76). In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 19, 1995:99.
46. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 1997;41:841-3.
47. Espinel-Ingroff A, Palacio A, Moore M. A comparison of the in vitro activity for the new triazole voriconazole with those of three established agents against dermatophytes and other molds (abstract J-19a). In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 25, 1998:456.
48. Schwartz S, Milatovic D, Theil E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997;97:663-5.
49. Hegener P, Troke PF, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998;12:2227-41.
50. Verweij PE, Brinkman K, Kremer HPH, Kullberg B, Meis JFGM. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol 1999;37:1186-9.
51. Patterson BE, Coates PE, UK-109-496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man (abstract F78). In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 18, 1995:126.
52. Sugar AM, Liu X-P. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol 2000;38:209-12.
53. Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997;41:13-6.
54. George D, Miniter P, Andriole VT. Efficacy of UK-109.496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1996;40:86-91.
55. Hitchcock CA, Andrews RJ, Lewis BGH, Troke PF. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Cryptococcus (abstract F75). In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 18, 1995:126.
56. Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Patterson TF. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 2000;44:2865-8.
57. Poza G, Montoya J, Redondo C, Ruiz J, Vila N, Rodriguez-Tudela JL, et al. Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin Infect Dis 2000;30:981-2.
58. Patterson BE, Roffey S, Jezequel SG, Jones B. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man (abstract F79). In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 18, 1995:126.
59. Ghahramani P, Purkins L, Wood ND, Love ER, Eve MD, Fielding A. Drug interactions between voriconazole and phenytoin (abstract 847). In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 18, 2000:24.
60. Ghahramani P, Wood ND, Kleinermans D, Love ER. No significant pharmacokinetic interactions between voriconazole and indinavir. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 18, 2000:24.
61. Romero AJ, Le Pogamp P, Nilsson L, Wood N. Effect of voriconazole on the pharmacokinefics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71:226-34.
62. Ghahramani P, Purkins L, Kleinermans D, Wood ND, Nichols DJ. Voriconazole potentiates warfarin-induced prolongation of prothrombin time (abstract 846). Presented at: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 18, 2000:24.
63. Ghahramani P, Purkins L, Wood ND, Kleinermans D, Nichols DJ. The pharmacokinetics of voriconazole and its effect on prednisolone disposifion (abstract 842). Presented at: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 18, 2000:24.
64. Ghahramani P, Purkins L, Kleinermans D, Wood ND, Nichols DJ. Voriconazole does not affect the pharmacokinetics of digoxin (abstract 849). Presented at: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 18, 2000:25.
65. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
66. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
67. FDA Antiviral Drugs Advisory Committee. Briefing document for voriconazole (oral and intravenous formulations). October 4, 2001. www.fda.gov/ohrms/dockets/ac/01/briefings/3792b2_01_Pfizer.pdf (accessed 2001 Dec 10).
68. Swift AC, Denning DW. Skull base osteitis following fungal sinusitis. J Laryngol Otol 1998;112:92-7.
69. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, Lutsar I. Voriconazole for the treatment of S. apiospermum and S. prolificans infection (abstract 305). In: Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, September 8, 2000:93.
70. Girmenia C, Luzi G, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol 1998;36:1436-8.
71. Jabado N, Casanova JL, Haddad E, Dulieu F, Fournet JC, Dupont B, et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis 1998;27:1437-41.
72. Muñoz P, Marin M, Tornero P, Rabadan PM, Rodriguez-Creixems M, Bouza E. Successful outcome of Scedosporium aspiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000;31:499-501.
73. Nesky MA, McDougal EC, Peacock JE Jr. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis 2000;31:673-7.
74. Reis A, Sundmacher R, Tintelnot K, Agostini H, Jenson HE, Althaus C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol 2000;84:932-3.
75. Heitmann L, Cometta A, Hurni M, Aebischer N, Tschan-Schild I, Bille J. Right-sided pacemaker-related endocarditis due to Acremonium species. Clin Infect Dis 1997:25:158-60.
76. Hilmarsdottir I, Thorsteinsson SB, Asmundsson P, Bodvarsson M, Arnadottir M. Cutaneous infection caused by Paecilomyces lilacinus in a renal transplant patient: treatment with voriconazole. Scand J Infect Dis 2000;32:331-2.
77. Perfect JR, Lutsar I, Gonzalez-Ruiz A. Voriconazole for the treatment of resistant and rare fungal infections (abstract 303). In: Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, September 8, 2000:93.
78. Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, et al. A randomized double-blind double-dummy multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447-54.
79. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
80. Powers JH, Dixon CA, Goldberger M. Decisions about voriconazole versus liposomal amphotericin B (letter). N Engl J Med 2002;346:1495-502.
81. Johnson JR. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med 2002;346:1745-7.
82. Walsh TJ, Lutsar I, Driscoll T, Dupont G, Roden M, Ghahramani P, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240-8.
83. Cardinale V, ed. Drug topics red book. Montvale, NJ: Medical Economics, 2002, November update.